Starting with the introductory presentation of autobiography of Alois Alzheimer, this review summarized various endeavors to treat Alzheimer’s disease in the past, at present and in the near future. Surprisingly, it is not explicitly documented when specific treatment for Alzheimer’s disease (AD)began. Various nootropics were in common use in Japan in the 70’s and 80’s while vitamin E, selegiline, gingko biloba, estrogen and NSAIDs have been tried as therapeutic strategies for AD, but unfortunately without establishing convincing evidence. Since the advent of tacrine in 1983, the era of cholinesterase inhibitors(ChEIs)has begun. Donepezil hydrochloride was introduced to Japanese AD patients in 1999. Two other ChEIs, galantamine and rivastigmine, had to wait for over 10 years before being approved in Japan and these medications will be on market in 2011. The year of 2011 is also highlighted by approval of NMDA receptor antagonist memantine in this country. Combination therapy of memantine and a ChEI (donepezil)is suggested effective in severe AD patients when either one has lost initial efficacy. In order to surmount the limitations of ChEIs and memantine as symptomatic treatments, big expectations are directed toward causative therapies that reduce amount of beta-amyloid and phosphorylated tau. Preventive strategies to reduce monomers, oligomers and soluble fibrils may include a-secretase agonist, b and g-secretase inhibitors and substances that reduce amyloid aggregation or accelerate degradation and disposal of amyloid.Contrary to theoretical righteousness and good hope for successful application to humans, some g-secretase inhibitors and modulators have been branded as non-effective and withdrawn from clinical trials. Amyloid vaccination is another expectation for the future treatment of AD both in the clinical and preclinical stages. It is a well-known disappointment that AN-1792 with adjuvants QS 21/ polysorbate-80 caused lethal encephalitis among antibody-positive responders, leading to premature termination of the clinical trial. Since then other vaccination methods have been investigated : passive immunization with monoclonal antibodies and active oral immunization with non-pathological vector adenovirus loaded with amyloid DNA that, when taken by mouth, stimulates lymphocytes within the epithelial cells of colon and produces antibodies. Besides lethal encephalitis, amyloid vaccination also suffers from a generally low responding rate(20 to 25%). With regard to the use of monoclonal antibodies, high cost, need for repeated intravenous administration and higher incidents of intracerebral microbleeds may limit their usefulness. Strategies to reduce phosphorylated tau may include the use of inhibitors of tau kinases that accelerate phosphorylation and inhibition of degrading enzymes for phosphatases that de-phosphorylate abnormal tau. Methylene blue(methylthioninium chloride : Rember)is one of the promising agents that suppress tau aggregation. Some other symptomatic treatments with latrepirdine(Dimebon), and inhibitors for phosphodiesterases, RAGE and hydroxytryptamine receptors are also discussed.
View full abstract